NCT06763952 Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
| NCT ID | NCT06763952 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Diabetic Retinopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 6,900 participants |
| Start Date | 2026-10-01 |
| Primary Completion | 2030-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6,900 participants in total. It began in 2026-10-01 with a primary completion date of 2030-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.
Eligibility Criteria
Clinics Inclusion Criteria: * Clinic must be from a health system with at least two clinics that meet eligibility criteria and will agree to join. * Number of unique patients with diabetes should be \>550 over any continuous 15-month period prior to the clinic providing a letter of support to participate in the trial. * No point-of-care screening system in use for DR. * Have an electronic health record to track patient data and agree to share limited data set as requested. * Have a member of the clinical team who can commit to serving as the clinic champion for this study. * Have the IT infrastructure to deploy an artificial-intelligence-based eye camera in the clinic. Patient Inclusion Criteria: * Diagnosis of type 1 or 2 diabetes * No known diabetic retinopathy * No diabetic retinopathy screening in the past 12 months Patient Exclusion Criteria: * Have a documented DR screening in the electronic health record within 12 months of the date of the primary care visit * Contraindication includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion * Pregnant
Contact & Investigator
Roomasa Channa
PRINCIPAL INVESTIGATOR
UW School of Medicine and Public Health
Frequently Asked Questions
Who can join the NCT06763952 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06763952 currently recruiting?
Yes, NCT06763952 is actively recruiting participants. Contact the research team at bahrainian@wisc.edu for enrollment information.
Where is the NCT06763952 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06763952 clinical trial?
NCT06763952 is sponsored by University of Wisconsin, Madison. The principal investigator is Roomasa Channa at UW School of Medicine and Public Health. The trial plans to enroll 6,900 participants.